| Page 51 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series

Author(s): 
Martynova A, Chiu V, Mert M, Hermel D, Weitz IC
Primary Author: 
Martynova A
Journal Title: 
Annals of Hematology
Original Publication Date: 
Jan 2021

First-line treatment of

Bone Marrow Disease(s): 

One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

Author(s): 
Kulasekararaj AG, Hill A, Langemeijer S, Wells R, González Fernández FA, Gaya A, Ojeda Gutierrez E, Piatek CI, Mitchell L, Usuki K, Bosi A, Brodsky RA, Ogawa M, Yu J, Ortiz S, Röth A, Lee JW, Peffault de Latour R.
Primary Author: 
Kulasekararaj AG
Journal Title: 
European Journal of Haematology
Original Publication Date: 
Dec 2020

Ravulizumab every 8 weeks showed non-inferiority to eculizumab every 2 weeks in a 26-week, phase 3, randomized controlled trial in adults with

Bone Marrow Disease(s): 

Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria

Author(s): 
Gurnari C, Graham AC, Efanov A, Pagliuca S, Durrani J, Awada H, Patel BJ, Lichtin AE, Visconte V, Sekeres MA, Maciejewski JP
Primary Author: 
Gurnarci C
Journal Title: 
Blood, cells, molecules & diseases
Original Publication Date: 
Dec 2020

While red blood cells (RBCs) and granulocytes have been more studied, platelets and reticulocytes are not commonly used in

Bone Marrow Disease(s): 

Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology

Author(s): 
Meryem Bektas, Catherine Copley-Merriman, Shahnaz Khan, Sujata P Sarda, Jamile M Shammo
Primary Author: 
Bektas, M
Journal Title: 
Journal of Managed care and specialty pharmacy
Original Publication Date: 
Dec 2020

The complement system is part of the innate immune response system, which comprises more than 50 distinct

Bone Marrow Disease(s):